Exelixis Stock Price, News & Analysis (NASDAQ:EXEL)

$29.10 +0.11 (+0.38 %)
(As of 02/23/2018 02:06 PM ET)
Previous Close$29.10
Today's Range$28.96 - $29.39
52-Week Range$18.03 - $32.50
Volume1.66 million shs
Average Volume2.66 million shs
Market Capitalization$8.58 billion
P/E Ratio58.96
Dividend YieldN/A
Beta1.84

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone+1-650-8377000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.32%
Quick Ratio4.27%

Price-To-Earnings

Trailing P/E Ratio58.9591836734694
Forward P/E Ratio59.39
P/E Growth0.81

Sales & Book Value

Annual Sales$191.45 million
Price / Sales44.97
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book93.87

Profitability

Trailing EPS$0.49
Net Income$-70,220,000.00
Net Margins36.80%
Return on Equity105.47%
Return on Assets27.22%

Miscellaneous

Employees287
Outstanding Shares295,850,000

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Zacks' consensus estimate of $0.08 by $0.18. The biotechnology company earned $152.50 million during the quarter, compared to analysts' expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company's revenue for the quarter was up 145.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2018?

12 equities research analysts have issued 1 year target prices for Exelixis' stock. Their predictions range from $26.00 to $39.00. On average, they anticipate Exelixis' share price to reach $31.71 in the next twelve months. View Analyst Ratings for Exelixis.

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. Cann analysts commented, "Exelixis announced today an amendment to the protocol for the phase Ib trial of Cabometyx (cabozantinib) in combination with atezolizumab (Tecentriq) in patients with locally advanced or metastatic solid tumors. Exelixis reported the amendment adds four new expansion cohorts to the trial, which will now include patients with non- small cell lung cancer (NSCLC) and castration-resistant prostate cancer (CRPC), in addition to previously included patients with renal cell carcinoma (RCC) and urothelial carcinoma (UC). The primary objective in the expansion stage of this trial remains to determine the objective response rate in each cohort. Exelixis confirmed the original trial protocol included four expansion cohorts, which will remain in the amended study unchanged." (1/4/2018)
  • 2. According to Zacks Investment Research, "Exelixis' lead drug Cabometyx posted strong sales in the first nine months of 2017 thereby underlying the increasing demand for the drug. New patient market share in the second line plus setting increased to 38%. The recent FDA approval of Cabometyx for the treatment previously untreated advanced RCC should further boost demand. The drug performed impressively against widely used Sutent. We expect Cabometyx will pose a challenge to Sutent’s market share for first line RCC in 2018. The approval comes two months ahead of schedule. The drug is also being evaluated for advanced hepatocellular carcinoma (HCC) in the CELESTIAL study. Exelixis also has collaborations with Bristol-Myers and Roche on the development of the drug in combination with immunotherapy agents. Moreover, Exelixis’ share price has outperformed the industry in 2017. However, the company is heavily dependent on Cabometyx for growth." (1/2/2018)

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder (Age 68)
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director (Age 56)
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President (Age 49)
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer (Age 60)
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer (Age 56)
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary (Age 48)
  • Patrick Haley, Senior Vice President - Commercial (Age 41)
  • Charles M. Cohen Ph.D., Independent Director (Age 66)
  • Carl B. Feldbaum Esq., Independent Director (Age 73)
  • Alan M. Garber M.D. Ph.D., Independent Director (Age 61)

Who owns Exelixis stock?

Exelixis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Meditor Group Ltd (5.57%), BlackRock Inc. (5.52%), Jennison Associates LLC (1.43%), Two Sigma Advisers LP (1.21%), Renaissance Technologies LLC (1.04%) and Wells Fargo & Company MN (1.04%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Acadian Asset Management LLC, Meditor Group Ltd, Renaissance Technologies LLC, Two Sigma Advisers LP, First Trust Advisors LP, Gotham Asset Management LLC and Alps Advisors Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Jennison Associates LLC, Smith Asset Management Group LP, Caisse DE Depot ET Placement DU Quebec, Arrowstreet Capital Limited Partnership, Stephens Investment Management Group LLC, Bank of Montreal Can and Macquarie Group Ltd.. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $29.10.

How big of a company is Exelixis?

Exelixis has a market capitalization of $8.58 billion and generates $191.45 million in revenue each year. The biotechnology company earns $-70,220,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. Exelixis employs 287 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4811, United States. The biotechnology company can be reached via phone at +1-650-8377000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (EXEL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Exelixis (NASDAQ:EXEL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.55
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.71$31.71$31.29$25.08
Price Target Upside: 12.42% upside16.81% upside7.81% upside7.75% downside

Exelixis (NASDAQ:EXEL) Consensus Price Target History

Price Target History for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018William BlairReiterated RatingOutperformMediumView Rating Details
1/17/2018OppenheimerReiterated RatingHoldHighView Rating Details
1/4/2018CannReiterated RatingHoldMediumView Rating Details
12/21/2017SunTrust BanksReiterated RatingBuy$38.00HighView Rating Details
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $33.00N/AView Rating Details
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$33.00 -> $39.00N/AView Rating Details
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
9/22/2017Leerink SwannDowngradeOutperform -> Market Perform$34.00 -> $28.00HighView Rating Details
8/10/2017CowenReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche BankDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Exelixis (NASDAQ:EXEL) Earnings History and Estimates Chart

Earnings by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.12N/AView Earnings Details
11/1/2017Q3 2017$0.08$0.26$104.91 million$152.50 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)$0.37ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.17)($0.12)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.31)($0.25)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.27)($0.25)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.33)($0.22)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.41)($0.33)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.31)($0.36)ViewN/AView Earnings Details
3/4/2009Q4 2008($0.35)($0.36)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.41)($0.39)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.39)($0.43)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.37)($0.39)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.28)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Exelixis (NASDAQ:EXEL) Earnings Estimates

2018 EPS Consensus Estimate: $0.67
2019 EPS Consensus Estimate: $1.25
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.09$0.13$0.11
Q2 20183$0.11$0.15$0.14
Q3 20183$0.16$0.17$0.16
Q4 20183$0.21$0.36$0.26
Q1 20191$0.27$0.27$0.27
Q2 20191$0.30$0.30$0.30
Q3 20191$0.33$0.33$0.33
Q4 20191$0.35$0.35$0.35
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.48%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2018Alan M GarberDirectorSell15,000$30.30$454,500.0064,829View SEC Filing  
9/28/2017Gisela SchwabInsiderSell100,000$23.79$2,379,000.00View SEC Filing  
9/28/2017Jeffrey HessekielEVPSell27,302$24.28$662,892.56View SEC Filing  
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00518,273View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.0452,721View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00130,070View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.5078,110View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.001,238,471View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00238,180View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00160,070View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.5086,405View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00174,354View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00548,273View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00548,273View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00494,975View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.2036,473View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.0036,473View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.8436,473View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00333,700View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Exelixis (NASDAQ EXEL) News Headlines

Source:
DateHeadline
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and ExelixisToday’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis
finance.yahoo.com - February 22 at 3:14 PM
Will Cabometyx Fuel Exelixis (EXEL) Earnings in Q4 Again? - NasdaqWill Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again? - Nasdaq
www.nasdaq.com - February 22 at 5:13 AM
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?
finance.yahoo.com - February 21 at 3:10 PM
Forty Seven Inc. Appoints Kristine M. Ball to Board of Directors - PR Newswire (press release)Forty Seven Inc. Appoints Kristine M. Ball to Board of Directors - PR Newswire (press release)
www.prnewswire.com - February 20 at 3:07 PM
Novartis Psoriasis Drug Cosentyx Positive in SCALP StudyNovartis Psoriasis Drug Cosentyx Positive in SCALP Study
finance.yahoo.com - February 20 at 3:07 PM
Head to Head Comparison: Exelixis (EXEL) and Vaxart (VXRT)Head to Head Comparison: Exelixis (EXEL) and Vaxart (VXRT)
www.americanbankingnews.com - February 19 at 5:16 PM
AbbVie Presents New Data on Upadacitinib for Crohn's DiseaseAbbVie Presents New Data on Upadacitinib for Crohn's Disease
finance.yahoo.com - February 19 at 3:05 PM
Exelixis (EXEL) Scheduled to Post Earnings on MondayExelixis (EXEL) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM
Exelixis, Inc. (EXEL) Expected to Announce Quarterly Sales of $118.15 MillionExelixis, Inc. (EXEL) Expected to Announce Quarterly Sales of $118.15 Million
www.americanbankingnews.com - February 17 at 10:34 AM
Exelixis, Inc. (EXEL) Given Average Rating of "Buy" by BrokeragesExelixis, Inc. (EXEL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 17 at 5:30 AM
The case for Bristol-Myers Squibb - Motley FoolThe case for Bristol-Myers Squibb - Motley Fool
www.fool.com - February 16 at 3:10 PM
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues BeatAcorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
finance.yahoo.com - February 16 at 3:10 PM
Better Buy: Exelixis, Inc. vs. Bristol-Myers SquibbBetter Buy: Exelixis, Inc. vs. Bristol-Myers Squibb
www.fool.com - February 16 at 6:15 AM
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment ... - Business Wire (press release)Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment ... - Business Wire (press release)
www.businesswire.com - February 15 at 3:10 PM
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull OcalivaIntercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva
finance.yahoo.com - February 15 at 3:10 PM
 Brokerages Anticipate Exelixis, Inc. (EXEL) to Post $0.12 Earnings Per Share Brokerages Anticipate Exelixis, Inc. (EXEL) to Post $0.12 Earnings Per Share
www.americanbankingnews.com - February 15 at 5:10 AM
Exelixis Reports Positive Data From Thyroid Carcinoma Trial - Nasdaq - NasdaqExelixis Reports Positive Data From Thyroid Carcinoma Trial - Nasdaq - Nasdaq
www.nasdaq.com - February 15 at 5:10 AM
AVEO (AVEO) to Get $2 Million from EUSA Pharma for FotivdaAVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
finance.yahoo.com - February 15 at 5:10 AM
Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018
finance.yahoo.com - February 15 at 5:10 AM
Roche's Rituxan Gets Priority Review for Label ExpansionRoche's Rituxan Gets Priority Review for Label Expansion
finance.yahoo.com - February 15 at 5:10 AM
Exelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic Radioiodine-Refractory DTCExelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic Radioiodine-Refractory DTC
www.streetinsider.com - February 14 at 3:10 PM
Exelixis Reports Positive Data From Thyroid Carcinoma TrialExelixis Reports Positive Data From Thyroid Carcinoma Trial
finance.yahoo.com - February 14 at 3:10 PM
Catalyst Gets Positive FDA Advise on Firdapse NDA RefilingCatalyst Gets Positive FDA Advise on Firdapse NDA Refiling
finance.yahoo.com - February 14 at 3:10 PM
Exelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic ... - StreetInsider.comExelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic ... - StreetInsider.com
www.streetinsider.com - February 14 at 5:06 AM
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid CarcinomaExelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
finance.yahoo.com - February 14 at 5:06 AM
Today’s Research Reports on Trending Tickers: Exelixis and 22nd Century GroupToday’s Research Reports on Trending Tickers: Exelixis and 22nd Century Group
finance.yahoo.com - February 13 at 3:07 PM
Vertex's Third Cystic Fibrosis Treatment Gets FDA ApprovalVertex's Third Cystic Fibrosis Treatment Gets FDA Approval
finance.yahoo.com - February 13 at 3:07 PM
Pfizer’s Sutent Generated Higher Revenues in 4Q17Pfizer’s Sutent Generated Higher Revenues in 4Q17
finance.yahoo.com - February 13 at 3:07 PM
Exelixis (EXEL) Earns Outperform Rating from William BlairExelixis (EXEL) Earns Outperform Rating from William Blair
www.americanbankingnews.com - February 12 at 11:52 AM
FDA Okays J&J's Prostate Cancer Drug in First-Line SettingFDA Okays J&J's Prostate Cancer Drug in First-Line Setting
finance.yahoo.com - February 9 at 3:11 PM
Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 - Business Wire (press release)Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 - Business Wire (press release)
www.businesswire.com - February 9 at 5:01 AM
Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018
finance.yahoo.com - February 9 at 5:01 AM
Theravance, J&J Ink Deal for Inflammatory Intestinal DrugTheravance, J&J Ink Deal for Inflammatory Intestinal Drug
finance.yahoo.com - February 8 at 3:10 PM
Keryx (KERX) Loss Wider Than Expected in Q4, Stock DownKeryx (KERX) Loss Wider Than Expected in Q4, Stock Down
finance.yahoo.com - February 8 at 3:10 PM
Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without ... - Business Wire (press release)Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without ... - Business Wire (press release)
www.businesswire.com - February 7 at 3:09 PM
Exelixis (EXEL) Announces Updated Phase 1 Trial Results for ... - StreetInsider.comExelixis (EXEL) Announces Updated Phase 1 Trial Results for ... - StreetInsider.com
www.streetinsider.com - February 7 at 3:09 PM
Exelixis Cabometyx shows treatment benefit in early-stage genitourinary tumor study; shares up 1%Exelixis' Cabometyx shows treatment benefit in early-stage genitourinary tumor study; shares up 1%
seekingalpha.com - February 7 at 10:18 AM
Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14
finance.yahoo.com - February 7 at 5:08 AM
5 of the Best Efficient Stocks for Your Portfolio5 of the Best Efficient Stocks for Your Portfolio
finance.yahoo.com - February 6 at 3:07 PM
Pfizer Files for Xtandi in Early Stage Prostate CancerPfizer Files for Xtandi in Early Stage Prostate Cancer
finance.yahoo.com - February 6 at 3:07 PM
Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer StudyBristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study
finance.yahoo.com - February 6 at 3:07 PM
Spectrum Pharma's Rolontis Positive in Pivotal Cancer StudySpectrum Pharma's Rolontis Positive in Pivotal Cancer Study
finance.yahoo.com - February 6 at 3:07 PM
5 Biotech Stocks Set to Trump Estimates This Earnings Season5 Biotech Stocks Set to Trump Estimates This Earnings Season
finance.yahoo.com - February 6 at 3:07 PM
Cramer's lightning round: Tableau Software is exactly the...Cramer's lightning round: Tableau Software is exactly the...
finance.yahoo.com - February 6 at 5:03 AM
Allergans Anti-Infective Drug Avycaz Receives Third FDA NodAllergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
www.msn.com - February 2 at 3:07 PM
Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority ReviewAlnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
finance.yahoo.com - February 2 at 3:07 PM
Puma, CANbridge Team Up to Commercialize Nerlynx in ChinaPuma, CANbridge Team Up to Commercialize Nerlynx in China
finance.yahoo.com - February 2 at 3:07 PM
Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & AlecensaRoche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
finance.yahoo.com - February 1 at 3:01 PM
Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis LabelAmgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label
finance.yahoo.com - January 31 at 3:09 PM
Puma & Medison Team Up to Commercialize Nerlynx in IsraelPuma & Medison Team Up to Commercialize Nerlynx in Israel
finance.yahoo.com - January 31 at 3:09 PM

SEC Filings

Exelixis (NASDAQ:EXEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Exelixis (NASDAQ EXEL) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.